Functional and molecular evidence of myelin- and neuroprotection by thyroid hormone administration in experimental allergic encephalomyelitis

Neuropathology and Applied Neurobiology

Volumn 38, Issue 5, 2012, Pages 454-470

  Dell'Acqua, M L ^a   Lorenzini, L ^e   D'Intino, G ^e   Sivilia, S ^e   Pasqualetti, P ^b   Panetta, V ^b   Paradisi, M ^e   Filippi, M M ^b   Baiguera, C ^f   Pizzi, M ^f   Giardino, L ^e   Rossini, P M ^c,d   Calza L ^e  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Experimental allergic encephalomyelitis; Neuroprotection; Remyelination; Somatosensory evoked potentials; Thyroid hormone

Indexed keywords

LIOTHYRONINE; MYELIN; NEUROFILAMENT PROTEIN; TAU PROTEIN; THYROID HORMONE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DARK AGOUTI RAT; DRUG DOSE COMPARISON; ELECTROSTIMULATION; EVOKED SOMATOSENSORY RESPONSE; FEMALE; LUMBAR SPINAL CORD; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE CONDUCTION; NEUROFILAMENT; NEUROPROTECTION; NEUROPSYCHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; AXONS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MYELIN SHEATH; NEUROPROTECTIVE AGENTS; RATS; SPINAL CORD; THYROID HORMONES; TRIIODOTHYRONINE;

EID: 84863589965     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01228.x     Document Type: Article

References (90)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 378: 1786-801.
2. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-89.
3. Lassmann H, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-18.
4. Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther 2010; 126: 82-93.
5. Duncan ID, Brower A, Kondo Y, Curlee JF Jr, Schultz RD. Extensive remyelination of the CNS leads to functional recovery. Proc Natl Acad Sci U S A 2009; 106: 6832-36.
6. Miller RH, Mi S. Dissecting demyelination. Nat Neurosci 2007; 10: 1351-54.
7. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-55.
8. Nishiyama A, Komitova M, Suzuki R, Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci 2009; 10: 9-22.
9. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 2002; 125: 338-49.
10. Wilson HC, Scolding NJ, Raine CS. Co-expression of PDGF alpha receptor and NG2 by oligodendrocyte precursors in human CNS and multiple sclerosis lesions. J Neuroimmunol 2006; 176: 162-73.
11. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Brück W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008; 131: 1749-58.
12. Dubois-Dalcq M, Williams A, Stadelmann C, Stadelmann C, Stankoff B, Zalc B, Lubetzki C. From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases. Brain 2008; 131: 1686-700.
13. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5: 22-31.
14. Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003; 60: 1073-81.
15. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008; 131: 1464-77.
16. Durand B, Raff M. A cell-intrinsic timer that operates during oligodendrocyte development. Bioessays 2000; 22: 64-71.
17. Bernal J. Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab 2007; 3: 249-59.
18. Calzà L, Fernandez M, Giardino L. Cellular approaches for stimulating CNS remyelination: thyroid hormone to promote myelin repair via endogenous stem and precursor cells. J Mol Endocrinol 2010; 44: 13-23.
19. Calzà L, Fernandez M, Giuliani A, Pirondi S, D'Intino G, Manservigi M, De Sordi N, Giardino L. Stem cells and nervous tissue repair: from in vitro to in vivo. Prog Brain Res 2004; 146: 75-91.
20. Fernandez M, Giuliani A, Pirondi S, D'Intino G, Giardino L, Aloe L, Levi-Montalcini R, Calzà L. Thyroid hormone administration facilitates remyelination in chronic experimental demyelinating-inflammatory disease. Proc Natl Acad Sci U S A 2004; 101: 16363-68.
21. Fernandez M, Pirondi S, Manservigi M, Giardino L, Calzà L. Thyroid hormone participates in the regulation of neural stem cells and oligodendrocyte precursor cells in the central nervous system of adult rat. Eur J Neurosci 2004; 20: 2059-70.
22. Fernández M, Paradisi M, Del Vecchio G, Giardino L, Calzà L. Thyroid hormone induces glial lineage in neurospheres derived from healthy and pathological rat brain: implications for remyelination enhancing therapies. Int J Dev Neurosci 2009; 27: 769-78.
23. Franco PG, Silvestroff L, Soto EF, Pasquini JM. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol 2008; 212: 458-67.
24. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, Guignard B, Parizel N, Grucker D, Boehm N, Miller RH, Ghandour MS. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 2008; 28: 14189-201.
25. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953-7.
26. Calzà L, Giardino L, Pozza M, Micera A, Aloe L. Time-course changes of nerve growth factor, corticotropin-releasing hormone, and nitric oxide synthase isoforms and their possible role in the development of inflammatory response in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 1997; 94: 3368-73.
27. Senoz S, Kutukcu Y, Aydin A, Yildiz O. Acetyl salicylic acid improves somatosensory evoked potentials in streptozotocin-diabetic rats. Diabetes Res Clin Pract 1999; 46: 191-6.
28. I-Ming J. The effects from lumbar nerve root transection in rats on spinal somatosensory and motor-evoked potentials. Spine 2004; 29: 147-55.
29. Bir LS, Ercan S. Effects of intrathecal anandamide on somatosensory evoked responses in rats. Exp Neurol 2006; 197: 386-90.
30. Zandieh S, Hopf R, Redl H, Schlag MG. The effect of ketamine/xylazine anaesthesia on sensory and motor evoked potentials in the rat. Spinal Cord 2003; 41: 16-22.
31. Schlag MG, Hopf R, Redl H. Serial recording of sensory, corticomotor, and brainstem-derived motor evoked potentials in the rat. Somatosens Mot Res 2001; 18: 106-16.
32. Cabrelle A, Dell'Aica I, Melchiori L, Carraro S, Brunetta E, Niero R, Scquizzato E, D'Intino G, Calzà L, Garbisa S, Agostini C. Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease. J Leukoc Biol 2008; 83: 212-19.
33. Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, Foster CA. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74: 307-31.
34. Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJ, Giovannoni G, Compston DA, Baker D, Spillantini MG, Chandran S. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008; 131: 1736-48.
35. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong CX. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett 2006; 580: 6269-74.
36. El-faramawy YA, El-banouby MH, Sergeev P, Mortagy AK, Amer MS, Abdel-tawab AM. Changes in glutamate decarboxylase enzyme activity and tau-protein phosphorylation in the hippocampus of old rats exposed to chronic mild stress: reversal with the neuronal nitric oxide synthase inhibitor 7-nitroindazole. Pharmacol Biochem Behav 2009; 91: 339-44.
37. Baas D, Legrand C, Samarut J, Flamant F. Persistence of oligodendrocyte precursor cells and altered myelination in optic nerve associated to retina degeneration in mice devoid of all thyroid hormone receptors. Proc Natl Acad Sci U S A 2002; 99: 2907-11.
38. O'Shea PJ, Williams GR. Insight into the physiological actions of thyroid hormone receptors from genetically modified mice. J Endocrinol 2002; 175: 553-70.
39. Obregon MJ, Calvo RM, Del Rey FE, de Escobar GM. Ontogenesis of thyroid function and interactions with maternal function. Endocr Dev 2007; 10: 86-98.
40. Baas D, Bourbeau D, Sarliève LL, Ittel ME, Dussault JH, Puymirat J. Oligodendrocyte maturation and progenitor cell proliferation are independently regulated by thyroid hormone. Glia 1997; 19: 324-32.
41. Rogister B, Ben-Hur T, Dubois-Dalcq M. From neural stem cells to myelinating oligodendrocytes. Mol Cell Neurosci 1999; 14: 287-300.
42. Durand B, Gao FB, Raff M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J 1997; 16: 306-17.
43. Lü HZ, Wang YX, Li Y, Fu SL, Hang Q, Lu PH. Proliferation and differentiation of oligodendrocyte progenitor cells induced from rat embryonic neural precursor cells followed by flow cytometry. Cytometry 2008; 3: 754-60.
44. Raff M. The mystery of intracellular developmental programmes and timers. Biochem Soc Trans 2006; 34: 663-70.
45. Papaioannou M, Melle C, Baniahmad A. The coregulator Alien. Nucl Recept Signal 2007; 5: e008.
46. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 2008; 68: 610-19.
47. Sarliève LL, Rodríguez-Peña A, Langley K. Expression of thyroid hormone receptor isoforms in the oligodendrocyte lineage. Neurochem Res 2004; 29: 903-22.
48. Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001; 81: 871-927.
49. Calzà L, Fernandez M, Giuliani A, Aloe L, Giardino L. Thyroid hormone activates oligodendrocyte precursors, increases a myelin forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 2002; 99: 3258-63.
50. Calzà L, Fernandez M, Giuliani A, D'Intino G, Pirondi S, Sivilia S, Paradisi M, Desordi N, Giardino L. Thyroid hormone and remyelination in adult central nervous system: a lesson from an inflammatory-demyelinating disease. Brain Res Brain Res Rev 2005; 48: 339-46.
51. Giardino L, Giuliani A, Fernandez M, Calzà L. Spinal motoneuron distress during experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol 2004; 30: 522-31.
52. D'Intino G, Lorenzini L, Fernandez M, Taglioni A, Perretta G, Del Vecchio G, Villoslada P, Giardino L, Calzà L. Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism. J Neuroendocrinol 2011; 23: 778-90.
53. Pluchino S, Muzio L, Imitola J, Deleidi M, Alfaro-Cervello C, Salani G, Porcheri C, Brambilla E, Cavasinni F, Bergamaschi A, Garcia-Verdugo JM, Comi G, Khoury SJ, Martino G. Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain 2008; 131: 2564-78.
54. Dong H, Yauk CL, Rowan-Carroll A, You SH, Zoeller RT, Lambert I, Wade MG. Identification of thyroid hormone receptor binding sites and target genes using ChIP-on-chip in developing mouse cerebellum. PLoS ONE 2009; 4: e4610.
55. Jones SA, Jolson DM, Cuta KK, Mariash CN, Anderson GW. Triiodothyronine is a survival factor for developing oligodendrocytes. Mol Cell Endocrinol 2003; 199: 49-60.
56. Bruce CC, Zhao C, Franklin RJ. Remyelination - an effective means of neuroprotection. Horm Behav 2010; 57: 56-62.
57. Rossini PM, Basciani M, Di Stefano E, Febbo A, Mercuri N. Short-latency scalp somatosensory evoked potentials and central spine to scalp propagation characteristics during peroneal and median nerve stimulation in multiple sclerosis. Electroencephalogr Clin Neurophysiol 1985; 60: 197-206.
58. Stanley GP, Pender MP. The pathophysiology of chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Brain 1991; 114: 1827-53.
59. Waxman SG. Determinants of conduction velocity in myelinated nerve fibers. Muscle Nerve 1980; 3: 141-50.
60. Rossini PM, Zarola F, Floris R, Bernardi G, Perretti A, Pelosi L, Caruso G, Caramia MD. Sensory (VEP, BAEP, SEP) and motor-evoked potentials, liquoral and magnetic resonance findings in multiple sclerosis. Eur Neurol 1989; 29: 41-7.
61. Abbruzzese G, Cocito L, Ratto S, Leandri M, Favale E. A reassessment of sensory evoked potential parameters in multiple sclerosis: a discriminant analysis approach. J Neurol Neurosurg Psychiatry 1981; 44: 133-9.
62. Bando Y, Takakusaki K, Ito S, Terayama R, Kashiwayanagi M, Yoshida S. Differential changes in axonal conduction following CNS demyelination in two mouse models. Eur J Neurosci 2008; 28: 1731-42.
63. Blakemore WF. Pattern of remyelination in the CNS. Nature 1974; 249: 577-8.
64. McDonald WI. Mechanisms of functional loss and recovery in spinal cord damage. Ciba Found Symp 1975; 34: 23-33.
65. Crawford DK, Mangiardi M, Xia X, López-Valdés HE, Tiwari-Woodruff SK. Functional recovery of callosal axons following demyelination: a critical window. Neuroscience 2009; 164: 1407-21.
66. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004; 117: 5721-29.
67. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, Smith KJ. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006; 253: 1542-51.
68. Papadopoulos D, Pham-Dinh D, Reynolds R. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol 2006; 197: 373-85.
69. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 2008; 118: 1532-43.
70. Gresle MM, Shaw G, Jarrott B, Alexandrou EN, Friedhuber A, Kilpatrick TJ, Butzkueven H. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J Neurosci Res 2008; 86: 3548-55.
71. Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010; 220: 114-19.
72. Huizinga R, Gerritsen W, Heijmans N, Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 2008; 32: 461-70.
73. Hernández F, Avila J. Tauopathies. Cell Mol Life Sci 2007; 64: 2219-33.
74. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006; 116: 2571-9.
75. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeöld A, Bianco AC. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 2008; 29: 898-938.
76. St Germain DL, Galton VA, Hernandez A. Minireview: defining the roles of the iodothyronine deiodinases: current concepts and challenges. Endocrinology 2009; 150: 1097-107.
77. Liu CR, Li LY, Shi F, Zang XY, Liu YM, Sun Y, Kan BH. Effects of hyper- and hypothyroid on expression of thyroid hormone receptor mRNA in rat myocardium. J Endocrinol 2007; 195: 429-38.
78. Papanicolaou DA. Euthyroid sick syndrome and the role of cytokines. Rev Endocr Metab Disord 2000; 1: 43-8.
79. Fekete C, Gereben B, Doleschall M, Harney JW, Dora JM, Bianco AC, Sarkar S, Liposits Z, Rand W, Emerson C, Kacskovics I, Larsen PR, Lechan RM. Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome. Endocrinology 2004; 145: 1649-55.
80. Margaill I, Royer J, Lerouet D, Ramaugé M, Le Goascogne C, Li WW, Plotkine M, Pierre M, Courtin F. Induction of type 2 iodothyronine deiodinase in astrocytes after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 2005; 25: 468-76.
81. Boelen A, Mikita J, Boiziau C, Chassande O, Fliers E, Petry KG. Type 3 deiodinase expression in inflammatory spinal cord lesions in rat experimental autoimmune encephalomyelitis. Thyroid 2009; 19: 1401-6.
82. Boelen A, Kwakkel J, Wiersinga WM, Fliers E. Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake. J Endocrinol 2006; 191: 707-14.
83. Boelen A, Kwakkel J, Thijssen-Timmer DC, Alkemade A, Fliers E, Wiersinga WM. Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol 2004; 182: 315-23.
84. Kwakkel J, Wiersinga WM, Boelen A. Interleukin-1beta modulates endogenous thyroid hormone receptor alpha gene transcription in liver cells. J Endocrinol 2007; 194: 257-65.
85. Baur A, Bauer K, Jarry H, Köhrle J. Effects of proinflammatory cytokines on anterior pituitary 5′-deiodinase type I and type II. J Endocrinol 2000; 167: 505-15.
86. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-81.
87. Zeis T, Kinter J, Herrero-Herranz E, Weissert R, Schaeren-Wiemers N. Gene espression analysis of normal appearing brain tissue in an animal model for multiple sclerosis revealed grey matter alterations, but only minor white matter changes. J Neuroimmunol 2008; 205: 10-19.
88. Zandieh-Doulabi B, Platvoet-ter Schiphorst M, Kalsbeek A, Wiersinga WM, Bakker O. Hyper and hypothyroidism change the expression and diurnal variation of thyroid hormone receptor isoforms in rat liver without major changes in their zonal distribution. Mol Cell Endocrinol 2004; 219: 69-75.
89. Constantinou C, Margarity M, Valcana T. Region-specific effects of hypothyroidism on the relative expression of thyroid hormone receptors in adult rat brain. Mol Cell Biochem 2005; 278: 93-100.
90. Zych-Twardowska E, Wajgt A. Blood levels of selected hormones in patients with multiple sclerosis. Med Sci Monit 2001; 7: 1005-12.